FDA clears Baxter's AMIA peritoneal dialysis system

• The FDA issues 510(k) clearance for Baxter International's (NYSE:BAX) AMIA automated peritoneal dialysis (APD) system with the SHARESOURCE web-based remote connectivity platform for the treatment of end-stage renal disease (ESRD).
• The AMIA APD system combines voice guidance features and a touchscreen control panel with the two-way connectivity of SHARESOURCE, which allows doctors to access their home patients' treatment data and deliver prescriptions remotely. The commercial launch will commence this quarter.
• About 600K Americans live with ESRD.